| 1 |
NCT02881125 |
Active, not recruiting |
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma |
|
- Drug: Nortriptyline Hydrochloride
- Drug: Paclitaxel
|
Interventional |
Phase 1 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose, determined by the number of patients who experience a dose limiting toxicity
- Objective tumor response evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1
- Overall Survival
- Progression free survival
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT02881125 |
9618
NCI-2016-01197
P30CA015704 |
|
November 3, 2016 |
July 1, 2018 |
November 30, 2019 |
August 26, 2016 |
January 9, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 2 |
NCT02366741 |
Unknown † |
Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study |
|
- Radiation: Whole brain radiotherapy with reduced dose to the hippocampi
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of patients that complete a year of imaging, neuro-cognitive and clinical follow up after WBRT with HC sparing as a measure of feasibility to conduct a randomized study in this patient population.
- Number of patients with no changes in the neurocognitive tests score and QOL as a measure for the correlation between NCT and HC sparing.
- Number of patients with no changes in serum markers for neuronal damage and as a measure for reduced damage due to hippocampal sparing
- Number of patients with changes in imaging biomarkers (TRAM) and neurocognitive tests score decline as a measure for a potential correlation between the two.
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT02366741 |
SMC-1476-14 |
|
January 2015 |
January 2017 |
January 2017 |
February 19, 2015 |
April 19, 2016 |
|
- Sheba Medical Center
Ramat Gan, Israel
|
| 3 |
NCT00537511 |
Terminated
Has Results |
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide |
|
- Drug: Pomalidomide
- Drug: Cisplatin
- Drug: Etoposide
|
Interventional |
Phase 1
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase
- Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)
- (and 4 more...)
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00537511 |
CC-4047-SCLC-002 |
|
February 2008 |
November 2010 |
December 2010 |
October 1, 2007 |
May 10, 2013 |
April 17, 2013 |
- Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology
Cleveland, Ohio, United States - Pennsylvania State University
Hershey, Pennsylvania, United States - University of Texas Southwestern Medical Center
Dallas, Texas, United States - (and 3 more...)
|
| 4 |
NCT00412880 |
Completed |
BI 2536 Second Line Monotherapy in SCLC |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
|
- Objective tumor response evaluated according to the RECIST criteria by tumor measurements using standard imaging (CT, MRI)
- Progression-free survival
- Overall survival
- (and 4 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT00412880 |
1216.11 |
|
January 2007 |
June 2008 |
|
December 19, 2006 |
May 16, 2014 |
|
- 1216.11.007 Boehringer Ingelheim Investigational Site
Fayetteville, Arkansas, United States - 1216.11.003 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States - 1216.11.006 Boehringer Ingelheim Investigational Site
Evanston, Illinois, United States - (and 7 more...)
|
| 5 |
NCT00305942 |
Completed
Has Results |
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
|
- Drug: Topotecan
- Drug: carboplatin
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- GlaxoSmithKline
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
- Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
- Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
|
61 |
All |
18 Years and older (Adult, Senior) |
NCT00305942 |
SCRI LUN 117 |
|
March 2006 |
April 2009 |
November 2009 |
March 22, 2006 |
January 31, 2013 |
January 24, 2013 |
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - Northeast Arkansas Clinic
Jonesboro, Arkansas, United States - Florida Cancer Specialists
Fort Myers, Florida, United States - (and 13 more...)
|
| 6 |
NCT02608411 |
Terminated |
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) |
|
|
Interventional |
Phase 2 |
- Istituto Oncologico Veneto IRCCS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Disease control rate (DCR)
- (and 2 more...)
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT02608411 |
IOV-SCLC-1-2014 TIMES |
TIMES |
October 2015 |
October 2017 |
February 2019 |
November 18, 2015 |
June 12, 2017 |
|
- Istituto Oncologico Veneto
Padova, Italy
|
| 7 |
NCT02736916 |
Recruiting |
HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell Lung
|
- Radiation: HS-WBRT PCI
- Radiation: Conventional PCI
|
Interventional |
Not Applicable |
- General Hospital of Ningxia Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Evaluate delayed recall as assessed by the Hopkins Verbal Learning Test-Revised (HVTL-R) 4 months after hippocampal sparing during whole-brain radiotherapy (HS-WBRT) for PCI of limited stage small cell lung cancer patients.
- Evaluate the rate of brain metastasis in hippocampal region after HS-WBRT PCI for limited stage small cell lung cancer patients.
|
3 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02736916 |
Radiation Oncology 20160101 |
|
March 2016 |
March 2018 |
December 2018 |
April 13, 2016 |
April 13, 2016 |
|
- General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
|
| 8 |
NCT00191750 |
Completed |
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the antitumor activity for patients with both sensitive and refractory small cell lung cancer patients as measured by tumor response rate. To characterize the toxicities of pemetrexed in this patient population
- To better understand any side effects of pemetrexed
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT00191750 |
7209
H3E-US-S069 |
|
July 2004 |
|
September 2006 |
September 19, 2005 |
January 26, 2007 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Aurora, Colorado, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Chapel Hill, North Carolina, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Dallas, Texas, United States
|
| 9 |
NCT00126828 |
Completed |
Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer |
|
- Procedure: External beam radiotherapy
|
Interventional |
Phase 1
Phase 2 |
- AHS Cancer Control Alberta
- Cross Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- grade 3 RT toxicity rate
- disease free
- overall survival
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT00126828 |
LU-11-0031 / 17141
PCRP-07 |
|
January 2003 |
September 2007 |
October 2007 |
August 5, 2005 |
February 24, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 10 |
NCT01900951 |
Unknown † |
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer |
|
|
Interventional |
Phase 2 |
- Chinese PLA General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- One-year progress free survival
- Overall Response Rate (ORR)
- Safety
- time to progression
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01900951 |
TMS-01 |
|
January 2013 |
February 2016 |
June 2016 |
July 17, 2013 |
January 26, 2016 |
|
- PLA general hospital
BeiJing, Beijing, China
|
| 11 |
NCT00826644 |
Unknown † |
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient |
|
- Drug: Belotecan/Cisplatin
- Drug: Etoposide/Cisplatin
|
Interventional |
Phase 3 |
- Chonnam National University Hospital
- Chong Kun Dang Pharmaceutical
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer
- to assess the overall response duration
- To assess the time to progression
- to assess the overall survival
|
150 |
All |
19 Years to 80 Years (Adult, Senior) |
NCT00826644 |
CSCLC-0810 |
COMBAT |
January 2009 |
June 2012 |
December 2012 |
January 22, 2009 |
January 10, 2012 |
|
- Chonnam National University Hwasun Hospital
Hwasun-gun, Jeonnam, Korea, Republic of
|
| 12 |
NCT00359359 |
Completed |
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer |
|
- Drug: Sagopilone (BAY86-5302, ZK 219477)
- Drug: Cisplatin
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Safety measure to establish the MTD or RPDII dose of Sagopilone used in combination with cisplatin
- Phase 2: Efficacy measure
- Phase 1: PK of Sagopilone + Cisplatin
- (and 4 more...)
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT00359359 |
91495
2006-000067-29
310101 |
|
July 2006 |
March 2009 |
August 2009 |
August 2, 2006 |
November 4, 2014 |
|
- Gerlingen, Baden-Württemberg, Germany
- Löwenstein, Baden-Württemberg, Germany
- München, Bayern, Germany
- (and 7 more...)
|
| 13 |
NCT00324558 |
Terminated |
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) |
|
|
Interventional |
Phase 2 |
- Clinica Universidad de Navarra, Universidad de Navarra
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- efficacy: progression-free survival in months (measurements of the size of the effect will be done using the Kaplan Meier method and the difference between the means of this time)
- safety: will be the incidence, during randomized treatment period (from day 1 to the last day of treatment + 7 days), of major bleedings.
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT00324558 |
ICT-BEM-2004-01
2004-004722-27 (Nº EudraCT) |
|
June 2005 |
February 2010 |
September 2010 |
May 11, 2006 |
June 8, 2012 |
|
- Hospital Clínico Universitario de Puerto Real
Puerto Real, Cádiz, Spain - Hospital Universitario Reina Sofía
Cordoba, Córdoba, Spain - Hospital Son Llàtzer
Son Ferriol, Islas Baleares, Spain - (and 12 more...)
|
| 14 |
NCT00129974 |
Terminated
Has Results |
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer |
|
- Drug: pemetrexed and gemcitabine
|
Interventional |
Phase 2 |
- Tufts Medical Center
- Eli Lilly and Company
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Number of Participants With at Least One Adverse Event
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT00129974 |
7338 |
|
August 2005 |
October 2006 |
October 2006 |
August 12, 2005 |
June 16, 2017 |
June 16, 2017 |
- Tufts-New England Medical Center
Boston, Massachusetts, United States - Commonwealth Hematology/Oncology
Quincy, Massachusetts, United States - Baystate Medical Center
Springfield, Massachusetts, United States
|
| 15 |
NCT02034123 |
Terminated |
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events (AEs), serious AEs (SAEs), dose limiting toxicities (DLTs), dose reductions or delays, withdrawals due to toxicities as a measure of safety and tolerability- Part 1 Dose Escalation
- Changes in safety parameters: , laboratory values, vital signs, electrocardiograms (ECGs), and physical examinations as a measure of safety and tolerability- Part 1 Dose Escalation
- Disease control rate (DCR) - Part 2 Expansion
- (and 9 more...)
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT02034123 |
200858 |
|
February 4, 2014 |
April 18, 2017 |
April 18, 2017 |
January 13, 2014 |
April 5, 2018 |
|
- GSK Investigational Site
Saint Louis, Missouri, United States - GSK Investigational Site
Columbus, Ohio, United States - GSK Investigational Site
Nashville, Tennessee, United States - (and 5 more...)
|
| 16 |
NCT00294931 |
Completed |
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell Lung
|
- Drug: irinotecan
- Drug: carboplatin
- Drug: bevacizumab
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- Genentech, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- median time to progression
- overall toxicity
- overall response rate
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00294931 |
SCRI LUN 90
AVF3256s |
|
February 2006 |
May 2007 |
January 2009 |
February 22, 2006 |
June 28, 2010 |
|
- Florida Cancer Specialists
Fort Myers, Florida, United States - Oncology Hematology Care
Cincinnati, Ohio, United States - Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States - Tennessee Oncology, PLLC
Nashville, Tennessee, United States
|
| 17 |
NCT00037713 |
Completed |
Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG |
- Carcinoma, Small Cell Lung
|
|
Interventional |
Phase 3 |
- ImClone LLC
- Merck KGaA
- EORTC Lung Cancer Cooperative Group
- (and 6 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progression-free survival
- Safety
- (and 2 more...)
|
515 |
All |
18 Years and older (Adult, Senior) |
NCT00037713 |
SILVA EORTC 08971 |
|
September 1998 |
October 2002 |
October 2002 |
May 21, 2002 |
April 8, 2010 |
|
|
| 18 |
NCT00435578 |
Terminated |
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma |
- Carcinoma, Small Cell Lung
|
|
Interventional |
Phase 2 |
- Threshold Pharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00435578 |
TH-CR-304 |
|
February 2007 |
November 2007 |
November 2007 |
February 15, 2007 |
April 30, 2009 |
|
- California Cancer Center
Greenbrae, California, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - Karmanos Cancer Institute
Detroit, Michigan, United States
|
| 19 |
NCT02688036 |
Recruiting |
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC |
- Carcinoma, Small Cell
- Lung Neoplasms
|
- Radiation: hypofractionated concurrent chemoradiotherapy
- Radiation: conventionally fractionated concurrent chemoradiotherapy
|
Interventional |
Phase 3 |
- Chinese Academy of Medical Sciences
- Sun Yat-sen University
- Fudan University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- disease free survival
- local-regional failure (Incidence of tumor recurrence in local or regional area)
- toxicity (Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0)
|
860 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02688036 |
CH-L-045/2 |
|
February 2016 |
December 2019 |
May 2020 |
February 23, 2016 |
January 2, 2018 |
|
- Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences
Beijing, China
|
| 20 |
NCT02675088 |
Not yet recruiting |
Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell
- Lung Neoplasms
|
- Radiation: high-dose TRT
- Radiation: standard-dose TRT
|
Interventional |
Phase 3 |
- Chinese Academy of Medical Sciences
- Sun Yat-sen University
- Fudan University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- progression-free survival
- Incidence of tumor recurrence in local or regional area
- Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0
|
186 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02675088 |
CH-L-045/1 |
|
March 2016 |
December 2017 |
December 2019 |
February 5, 2016 |
February 8, 2016 |
|
|
| 21 |
NCT03092739 |
Active, not recruiting |
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
|
- Diagnostic Test: PD-L1 Immunocytochemistry (ICC)
- Diagnostic Test: PD-L1 Immunohistochemistry (IHC)
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Total Tumor Cells (TC) That Display Discernible PD-L1 Staining of any Intensity in Histological and Cytological Samples As Assessed Using PD-L1 IHC/ICC Assay
- Percentage of Total TC Within ten High-Power Fields (HPF) That Display Discernible PD-L1 Staining of any Intensity in Histological and Cytological Samples As Assessed Using PD-L1 IHC/ICC Assay
- Percentage of Total Tumor Area That Contain Tumor-Infiltrating Immune Cells of any Discernible PD-L1 Staining of any Intensity in Histological Samples As Assessed Using PD-L1 IHC Assay
- (and 2 more...)
|
200 |
All |
Child, Adult, Senior |
NCT03092739 |
MO29978 |
|
May 3, 2017 |
May 15, 2018 |
May 15, 2018 |
March 28, 2017 |
February 12, 2018 |
|
- Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci
Praha 2, Czechia - Universitätsklinikum Göttingen, Institut für Pathologie
Göttingen, Germany - Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc
Warszawa, Poland - (and 5 more...)
|
| 22 |
NCT01635400 |
Unknown † |
Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer |
- Small Cell Carcinoma of Lung
|
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Side effect of chemotherapy
- response rate of chemotherapy
|
50 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01635400 |
UGT1A1-01 |
|
June 2012 |
June 2014 |
June 2014 |
July 9, 2012 |
July 9, 2012 |
|
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
|
| 23 |
NCT00298896 |
Completed |
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer |
- Carcinoma, Small Cell
- Small Cell Lung Cancer
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response
- Safety
- Overall survival rate
- Biomarker correlation to clinical response
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT00298896 |
SPO-0006 |
|
February 2006 |
August 2007 |
June 2008 |
March 3, 2006 |
March 6, 2009 |
|
- University of California Davis
Sacramento, California, United States - Stanford University Medical Center
Stanford, California, United States - Rush University Medical Center
Chicago, Illinois, United States - (and 14 more...)
|
| 24 |
NCT00284154 |
Completed
Has Results |
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer |
- Carcinoma, Small Cell
- Lung Cancer
|
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
- Duration of Response, the Length of Time, in Months, That Protocol Treatment Produced an Objective Improvement in Patients' Disease
- Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
- Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
|
51 |
All |
18 Years and older (Adult, Senior) |
NCT00284154 |
SCRI LUN 122 |
|
January 2006 |
May 2009 |
November 2009 |
January 31, 2006 |
March 13, 2013 |
March 13, 2013 |
- Florida Cancer Specialists
Fort Myers, Florida, United States - Oncology Hematology Care
Cincinnati, Ohio, United States - Tennessee Oncology, PLLC
Nashville, Tennessee, United States
|
| 25 |
NCT00294190 |
Completed |
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer |
- Small Cell Lung Cancer
- Carcinoma, Small Cell
|
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- overall toxicity
- time to progression
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT00294190 |
SCRI LUN 120
105642 |
|
February 2006 |
September 2007 |
July 2009 |
February 20, 2006 |
December 10, 2012 |
|
- Northeast Arkansas Clinic
Jonesboro, Arkansas, United States - Florida Cancer Specialists
Fort Myers, Florida, United States - Watson Clinic Center for Cancer Care and Research
Lakeland, Florida, United States - (and 10 more...)
|
| 26 |
NCT00308529 |
Completed |
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell Lung
- Lung Cancer
|
- Drug: irinotecan
- Drug: carboplatin
- Drug: bevacizumab
- Procedure: Radiation Therapy
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- Genentech, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
- toxicity
- overall response rate
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT00308529 |
SCRI LUN 110
AVF3526s |
|
March 2006 |
April 2007 |
January 2009 |
March 29, 2006 |
June 22, 2010 |
|
- Florida Cancer Specialists
Fort Myers, Florida, United States - Oncology Hematology Care
Cincinnati, Ohio, United States - Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States - Tennessee Oncology, PLLC
Nashville, Tennessee, United States
|
| 27 |
NCT00046787 |
Completed |
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer |
- SCLC
- Carcinoma, Small Cell
|
- Drug: OSI-211 (Liposomal Lurtotecan)
|
Interventional |
Phase 2 |
- Astellas Pharma Inc
- OSI Pharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
47 |
All |
18 Years and older (Adult, Senior) |
NCT00046787 |
110-12 |
|
September 2002 |
|
February 2003 |
October 4, 2002 |
October 20, 2011 |
|
- Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States - University of Colorado Health Sciences Center
Denver, Colorado, United States - Baptist Hospital Regional Cancer Ctr.
Knoxville, Tennessee, United States - (and 7 more...)
|
| 28 |
NCT00469222 |
Completed |
Hypofractionated Radiotherapy for Small Cell Lung Cancer |
- Lung Neoplasm
- Small Cell Carcinoma
|
- Procedure: hypofractionated external beam
|
Interventional |
Phase 1 |
- AHS Cancer Control Alberta
- Cross Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates of acute grade 3 or higher radiotherapy toxicities
- Overall survival and disease free survival, patient related quality of life
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT00469222 |
LU-11-0072 / 23117 |
|
March 2007 |
April 2011 |
April 2011 |
May 4, 2007 |
February 25, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 29 |
NCT03083691 |
Enrolling by invitation |
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
|
- Drug: Nivolumab, Ipilimumab
|
Interventional |
Phase 2 |
- Lung Cancer Group Cologne
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.
- Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.
- Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
- (and 4 more...)
|
106 |
All |
18 Years and older (Adult, Senior) |
NCT03083691 |
Uni-Koeln-2785
2016-003334-25 |
|
April 5, 2017 |
March 2019 |
August 2020 |
March 20, 2017 |
May 12, 2017 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
| 30 |
NCT00923884 |
Completed |
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer |
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Small-Cell Lung
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of the association between polymorphisms in the enzymes ABCB1, CYP1B1, and CYP19 and clinical outcomes, with overall survival of greatest interest, in patients undergoing treatment for lung cancer.
|
546 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00923884 |
090103
09-C-0103 |
|
March 18, 2009 |
|
April 20, 2018 |
June 18, 2009 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 31 |
NCT02146170 |
Recruiting |
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors |
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Extrapulmonary Small Cell Cancer
- (and 2 more...)
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.
- Follow the natural history of patients with thoracic malignancies.
- Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic ...
|
2000 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02146170 |
140105
14-C-0105 |
|
May 8, 2014 |
April 30, 2024 |
April 30, 2025 |
May 23, 2014 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 32 |
NCT00263731 |
Recruiting |
Metabolomic Analysis of Lung Cancer |
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Small Cell Lung
|
|
Observational |
|
- James Graham Brown Cancer Center
- University of Louisville
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- metabolic profiles of cancerous vs. healthy lung tissue
- glycolytic metabolism in plasma
- metabolic markers in urine
- (and 3 more...)
|
750 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00263731 |
523.05
BCC-LUN-05-002 |
|
December 2005 |
December 2018 |
December 2018 |
December 9, 2005 |
November 23, 2016 |
|
- James Graham Brown Cancer Center, University of Louisville
Louisville, Kentucky, United States
|
| 33 |
NCT02487095 |
Recruiting |
Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers Amd Extrapulmonary Small Cell Cancers |
- Carcinoma, Non-Small -Cell Lung
- Ovarian Neoplasms
- Small Cell Lung Carcinoma
- (and 3 more...)
|
- Drug: Topotecan
- Drug: VX-970
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ph I: Maximum Tolerated Dose (MTD) of topotecan in combination with VX-970
- Ph II: Clinical Response Rate
|
70 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02487095 |
150150
15-C-0150 |
|
June 18, 2015 |
May 31, 2024 |
October 30, 2025 |
July 1, 2015 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 34 |
NCT00756639 |
Active, not recruiting |
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium |
|
- Radiation: Prophylactic Cranial Irradiation (PCI)
- Other: Brain X-ray
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Brain Metastasis Free Survival
|
31 |
All |
18 Years and older (Adult, Senior) |
NCT00756639 |
2007-0933
NCI-2012-01675 |
|
July 21, 2008 |
June 2019 |
June 2020 |
September 22, 2008 |
April 19, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 35 |
NCT00466232 |
Completed |
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer |
- Small Cell Carcinoma
- Lung Cancer
|
- Drug: Topotecan
- Drug: Sorafenib
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to determine the maximum tolerated dose of sorafenib up to the full active dose when combined with standard weekly dosing of topotecan in patients with recurrent small cell lung cancer and to
- characterize the toxicities associated with the combination of topotecan and sorafenib in this patient population
- To evaluate the objective response rate (CR, PR or stable disease)
- (and 3 more...)
|
16 |
All |
Child, Adult, Senior |
NCT00466232 |
3557-07-C |
|
April 2007 |
December 2009 |
March 2010 |
April 27, 2007 |
December 16, 2015 |
|
- Park Nicollet Institute
St. Louis Park, Minnesota, United States
|
| 36 |
NCT00907569 |
Completed |
Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer |
- Lung Neoplasm
- Small Cell Carcinoma
|
- Radiation: Hypofractionated Chest Radiotherapy
|
Interventional |
Phase 2 |
- AHS Cancer Control Alberta
- Cross Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 2-year overall survival
- Quality of life
- Patterns of Failure
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT00907569 |
24762 |
|
June 2009 |
April 2011 |
April 2011 |
May 22, 2009 |
February 22, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 37 |
NCT00447421 |
Terminated
Has Results |
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy |
- Small Cell Lung Cancer
- Carcinoma, Small Cell
- SCLC
|
- Drug: pemetrexed
- Drug: cisplatin
- Radiation: radiation
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Maximum Tolerated Dose
- Phase 2: Overall Response Rate
- Phase 1: Best Overall Response
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT00447421 |
11089
H3E-EW-S107 |
|
February 2007 |
May 2008 |
May 2008 |
March 14, 2007 |
October 28, 2009 |
August 26, 2009 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Leuven, Belgium - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Amsterdam, Netherlands - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Den Bosch, Netherlands - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Rotterdam, Netherlands
|
| 38 |
NCT01306045 |
Recruiting |
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
- Carcinoma, Thymic
|
- Drug: AZD6244
- Drug: MK-2206
- Drug: Lapatinib
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility of the use of tumor molecular profiling and targeted therapies in the treatment of NSCLC, SCLC, and Thymic Malignancies
- To estimate the response rate of molecular-profile directed treatments in NSCLC, SCLC, and Thymic Malignancies
|
600 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01306045 |
110096
11-C-0096 |
|
February 26, 2011 |
January 31, 2019 |
December 30, 2019 |
March 1, 2011 |
February 8, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 39 |
NCT00637624 |
Unknown † |
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
- Mesothelioma
|
- Drug: N-Acetylcysteine
- Drug: Placebo
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- The occurrence of peripheral neuropathy: with the peripheral neuropathy score (PNP-score) and the electrophysiological measurements. If no EMG is available, then audiometric measurements will be taken into account.
- haematological abnormalities
- creatinine clearance.
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00637624 |
LTC-510-100108-Bahce
CCMO: NL19614.091.07
EudraCT: 2007-002787-95 |
NAC-PNP |
March 2008 |
December 2011 |
February 2012 |
March 18, 2008 |
August 9, 2011 |
|
- Rijnstate Hospital
Arnhem, Gelderland, Netherlands
|
| 40 |
NCT00265200 |
Terminated
Has Results |
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer |
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Small Cell Lung
- Metastases
|
|
Interventional |
Phase 2 |
- University of Louisville
- James Graham Brown Cancer Center
- Novartis Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Average Percent Change From Baseline in TRAP Levels at 2 Weeks
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT00265200 |
565.04
BCC-LUN-04-002 |
|
February 2005 |
August 2009 |
December 2010 |
December 14, 2005 |
March 5, 2018 |
April 6, 2017 |
- James Graham Brown Cancer Center
Louisville, Kentucky, United States
|
| 41 |
NCT01470248 |
Completed
Has Results |
Study of Arsenic Trioxide in Small Cell Lung Cancer |
- Lung Cancer
- Cancer of Lung
- Pulmonary Cancer
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- Emory University
- Cephalon
- Teva Pharmaceuticals USA
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (RR)
- Clinical Benefit Rate (CBR)
- Progression-free Survival
- Overall Survival
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01470248 |
IRB00050301
WCI1988-11
K23CA164015 |
|
August 2011 |
January 2016 |
January 2016 |
November 11, 2011 |
April 5, 2017 |
March 8, 2017 |
- Emory University Winship Cancer Institute
Atlanta, Georgia, United States
|
| 42 |
NCT01970696 |
Recruiting |
International Ovarian & Testicular Stromal Tumor Registry |
- Ovarian Stromal Tumor
- Testicular Stromal Tumors
- Ovarian Small Cell Carcinoma
- DICER1 Syndrome
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Dana-Farber Cancer Institute
- (and 10 more...)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Other
|
- DICER1 mutations in ovarian and testicular stromal tumors
- Clinical factors associated with outcome in ovarian and testicular stromal tumors
- Pathologic and Genetic Correlations
|
200 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT01970696 |
International OTST Registry |
OTST |
December 2011 |
December 2020 |
|
October 28, 2013 |
November 6, 2017 |
|
- Children's Minnesota
Minneapolis, Minnesota, United States
|
| 43 |
NCT00469066 |
Completed |
Cone Beam CT Scanning in Lung and Bladder Cancer. |
- Lung Neoplasm
- Small Cell Carcinoma
- Bladder Carcinoma
|
|
Observational |
|
- AHS Cancer Control Alberta
- Cross Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00469066 |
LU-11-0073 |
|
May 2007 |
August 2009 |
April 2010 |
May 4, 2007 |
February 24, 2016 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 44 |
NCT00094978 |
Terminated |
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum |
- Carcinoma, Small Cell
- Carcinoma, Non-Small-Cell Lung
- Esophageal Neoplasms
- Mesothelioma
|
- Drug: Depsipeptide
- Drug: Flavopiridol (alvocidib)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT00094978 |
050010
05-C-0010 |
|
October 25, 2004 |
May 20, 2013 |
May 20, 2013 |
October 29, 2004 |
April 17, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 45 |
NCT00100256 |
Active, not recruiting |
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy |
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Neoplasm Recurrence, Local
|
- Drug: Rhenium (Re 188 P2045, BAY86-5284)
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of Rhenium 188 P2045
- Safety of Technetium Tc 99m P2045 and Rhenium Re 188 P2045
- Progression free survival in treated patients
|
60 |
All |
21 Years and older (Adult, Senior) |
NCT00100256 |
91168
306509 |
|
January 2004 |
June 2004 |
April 2020 |
December 28, 2004 |
August 15, 2017 |
|
- Iowa City, Iowa, United States
- Baltimore, Maryland, United States
|
| 46 |
NCT02995187 |
Recruiting |
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) |
|
- Drug: Apatinib Mesylate tablet
|
Interventional |
Phase 2 |
- Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Disease Control Rate
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
25 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02995187 |
CH-L-061 |
|
December 2016 |
May 2018 |
September 2018 |
December 16, 2016 |
September 7, 2017 |
|
- Chinese Academy of Medical Sciences
Beijing, China
|
| 47 |
NCT00003496 |
Terminated |
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer |
- Small Cell Lung Cancer Extensive Stage
|
- Drug: Antineoplaston therapy (Atengenal + Astugenal)
|
Interventional |
Phase 2 |
- Burzynski Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
4 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT00003496 |
CDR0000066535
BC-LA-07 |
|
March 7, 1996 |
February 5, 2004 |
February 5, 2004 |
January 27, 2003 |
September 28, 2017 |
|
- Burzynski Clinic
Houston, Texas, United States
|
| 48 |
NCT00006344 |
Withdrawn |
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer |
|
- Radiation: radiation therapy
|
Interventional |
Phase 3 |
- Virginia Commonwealth University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
|
0 |
All |
Child, Adult, Senior |
NCT00006344 |
CDR0000068152
P30CA016059
MCV-MCC-9912-2A
NCI-V00-1613 |
|
May 2000 |
December 2000 |
December 2000 |
May 24, 2004 |
May 19, 2015 |
|
- Massey Cancer Center
Richmond, Virginia, United States
|
| 49 |
NCT00003943 |
Completed |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. |
- Carcinoma of Unknown Primary
- Lung Cancer
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 2 |
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the one year progression-free survival
- Overall survival; safety of regimen; CR rate; lab correlates; pharmacokinetics
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT00003943 |
CDR0000067136
FCCC-98039
NCI-G99-1535 |
|
September 1998 |
November 2000 |
February 2003 |
May 3, 2004 |
April 17, 2013 |
|
- Johns Hopkins Oncology Center
Baltimore, Maryland, United States - Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
| 50 |
NCT01642251 |
Active, not recruiting |
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer |
- Extensive Stage Small Cell Lung Carcinoma
- Large Cell Lung Carcinoma
- Neuroendocrine Carcinoma
- (and 2 more...)
|
- Drug: Cisplatin
- Drug: Etoposide
- Other: Laboratory Biomarker Analysis
- (and 4 more...)
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of veliparib based on the incidence of dose-limiting toxicity as assessed by the Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- PFS (Phase II)
- Best objective response evaluated via RECIST 1.1 (Phase II)
- (and 2 more...)
|
168 |
All |
18 Years and older (Adult, Senior) |
NCT01642251 |
NCI-2012-01985
E2511
ECOG-E2511
CDR0000736704
U10CA180820
U10CA021115
U24CA196172 |
|
September 28, 2012 |
January 31, 2018 |
|
July 17, 2012 |
February 2, 2018 |
|
- Loma Linda University Medical Center
Loma Linda, California, United States - Stanford Cancer Institute Palo Alto
Palo Alto, California, United States - Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, United States - (and 425 more...)
|
Create an RSS feed from your search for:
Download the search results for: